Jinbo Bio exits the "exclusive era": first annual profit decline since listing
```
As the “leader” in the recombinant collagen track, Jinbo Bio’s 2025 performance report has caused the market to sense a hint of unease.
On April 30, Jinbo Bio released its 2025 financial report showing revenue for the period at 1.595 billion yuan, with a year-on-year growth of only